Logo
x

Search

Subscribe Now

Endo

Endo & Mallinckrodt Pharmaceuticals to Form a Combine Entity with $6.7B Cash-and-Stock

Endo & Mallinckrodt Pharmaceuticals to Form a Combine Entity with $6.7B Cash-and-Stock

  • March 18, 2025
Top 20 Generics Pharma Companies Based On 2020 Revenue

Top 20 Generics Pharma Companies Based On 2020 Revenue

  • October 28, 2021
PharmaShots Weekly Snapshot (Oct 19 - 23, 2020)

PharmaShots Weekly Snapshot (Oct 19 - 23, 2020)

  • October 23, 2020
Ethicon (J&J) Recalls Endo-Surgery Intraluminal Staplers Due to Complete Staple Line Failure

Ethicon (J&J) Recalls Endo-Surgery Intraluminal Staplers Due to Complete Staple Line Failure

  • May 20, 2019
GSK’s Jemperli Plus Chemotherapy Receives the EC’s Approval as a 1L Treatment of Primary Advanced or Recurrent Endometrial Cancer

    GSK’s Jemperli Plus Chemotherapy Receives the EC’s Approval as a 1L Treatment of Primary Advanced or Recurrent Endometrial Cancer

    • January 20, 2025
    Lilly at UEGW 2024: Mark Genovese in an Illuminating Dialogue Exchange with PharmaShots shares insights into VIVID-1 study

      Lilly at UEGW 2024: Mark Genovese in an Illuminating Dialogue Exchange with PharmaShots shares insights into VIVID-1 study

      • December 18, 2024
      GSK Reports the CHMP’s Positive Opinion of Jemperli Plus Chemotherapy for Indication Expansion to Endometrial Cancer

        GSK Reports the CHMP’s Positive Opinion of Jemperli Plus Chemotherapy for Indication Expansion to Endometrial Cancer

        • December 17, 2024
        Repare Therapeutics Reports the P-I (MYTHIC) Trial Data of Lunresertib Plus Camonsertib to Treat Gynecologic Cancers

          Repare Therapeutics Reports the P-I (MYTHIC) Trial Data of Lunresertib Plus Camonsertib to Treat Gynecologic Cancers

          • December 13, 2024
          Microbot Medical Reports Regulatory Submission for LIBERTY Endovascular Robotic System to the US FDA

            Microbot Medical Reports Regulatory Submission for LIBERTY Endovascular Robotic System to the US FDA

            • December 11, 2024
            Phanes Therapeutics’ PT217 Secures the US FDA’s Fast Track Designation for Neuroendocrine Prostate Cancer (NEPC)

              Phanes Therapeutics’ PT217 Secures the US FDA’s Fast Track Designation for Neuroendocrine Prostate Cancer (NEPC)

              • December 5, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.